ImprimisRx to feature new formulation and poster presentation on MKO Melt® at the upcoming American Academy of Ophthalmology...
16 Octubre 2018 - 6:00AM
Poster on data from a 611-patient study featuring
Imprimis’s MKO Melt to be presented
ImprimisRx, the ophthalmic-focused division of Imprimis
Pharmaceuticals, Inc. (NASDAQ: IMMY), today announced its
participation at the upcoming 2018 American Academy of
Ophthalmology (AAO) Annual Meeting to be held at the McCormick
Place Convention Center in Chicago, IL, October 26-30. The
American Academy of Ophthalmology is the world’s largest
association of eye physicians and surgeons, encompassing a
community of 32,000 medical doctors. More than 90 percent of
practicing ophthalmologists are AAO members. The annual
meeting includes a global community of innovators in the art and
science of ophthalmology in addition to game-changing research,
techniques, and technologies.
At the conference, attendees will have the opportunity to meet
with ImprimisRx representatives in Booth #4254 to learn about
Imprimis’s full portfolio of formulations, including a new
tropicamide and phenylephrine combination topical offering from its
FDA-registered 503B outsourcing facility. This formulation
further expands the company’s office-use portfolio of ophthalmic
focused compounded medications.
Maggie Jeffries, M.D., a board-certified anesthesiologist, will
be presenting a poster on Sunday October 28th at 12:45 pm at the
conference. The poster titled “Conscious sedation efficacy of
the novel medication, MKO Melt, during cataract surgery” will
summarize the results of her investigator led 611-patient IRB
approved prospective, controlled, randomized, three arm comparator
study. The purpose of the study was to compare the conscious
sedation efficacy of a non-opioid sublingual troche, Imprimis’s MKO
Melt, to diazepam and a diazepam/tramadol/ondansetron combination
during cataract surgery.
The MKO Melt (midazolam/ketamine/ondansetron) is a non-invasive,
non-opioid, patented, sublingual troche used typically by
physicians for short term procedures, with potentially 100 million
addressable procedures in the U.S. annually across multiple
verticals and a potential multi-billion-dollar opportunity.
Imprimis Pharmaceuticals recently formed a new subsidiary, Melt
Pharmaceuticals, Inc., which is pursuing the development of
505(b)(2) drug candidates for FDA approval based on the underlying
technology of the MKO Melt.
About Imprimis
Pharmaceuticals
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is
a commercial-stage pharmaceutical company based in San Diego,
California. In addition to owning the nation’s leading
ophthalmology pharmaceutical compounding business, ImprimisRx, the
Company holds large equity positions in Eton Pharmaceuticals,
Surface Pharmaceuticals and Melt Pharmaceuticals, companies
originally founded as subsidiaries of Imprimis. The Company
also owns royalty rights in certain 505(b)(2) drug candidates being
developed by Eton, Surface and Melt. For more information
about Imprimis, please visit the Investor Relations section of the
corporate website by clicking here.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Any statements in this release that
are not historical facts may be considered such "forward-looking
statements." Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties
which may cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Imprimis' filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its Quarterly Reports
on Form 10-Q. Such documents may be read free of charge on the
SEC's web site at www.sec.gov. Undue reliance should not be placed
on forward-looking statements, which speak only as of the date they
are made. Except as required by law, Imprimis undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made,
or to reflect the occurrence of unanticipated events.
No Imprimis compounded formulation is
FDA-approved. Other than drugs compounded at a registered
outsourcing facility, all Imprimis compounded formulations require
a prescription for an individually identified patient consistent
with federal and state laws.
Investor Contact:Jon
Pattonjpatton@imprimispharma.com858-704-4587
Media Contact:Deb
HollidayHolliday Communications,
Inc.deb@hollidaycommunications.net412-877-4519
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024